Reappraise role of lymph node status in patterns of recurrence following curative resection of gastric adenocarcinoma

Yihui Tang¹*, Jianxian Lin¹-2*, Junpeng Lin¹, Jiabin Wang¹-2, Jun Lu¹-2, Qiyue Chen¹-2, Longlong Cao¹-2, Mi Lin¹, Ruhong Tu¹, Changming Huang¹-2, Ping Li¹-2, Chaohui Zheng¹-2, Jianwei Xie¹-2

¹Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China; ²Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou 350108, China

*These authors contributed equally to this work.

Correspondence to: Ping Li, MD, PhD. Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, China. Email: pingli811002@163.com; Chaohui Zheng, MD, PhD. Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, China. Email: wwkzh@163.com; Jianwei Xie, MD, PhD. Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, China. Email: xjwhw2019@163.com.

Abstract

Objective: To examine the association between lymph node status and recurrence patterns in completely resected gastric adenocarcinoma.

Methods: We retrospectively assessed 1,694 patients who underwent curative gastrectomy from January 2010 to August 2014. Patients stratified according to lymph node status and recurrence patterns among different subgroups were compared.

Results: Of all, 517 (30.5%) patients developed recurrent disease, and complete data of recurrence could be obtained in 493 (95.4%) patients. For pN0 patients, the patterns of recurrence were different according to pT stage: locoregional recurrence was most common in patients with pT1−2 disease (57.1%), distant recurrence was most common in patients with pT3 disease (57.1%), and peritoneal recurrence was most common in patients with pT4a disease (66.7%). For pN+ patients, distant metastasis was most common pattern irrespective of pT stage. The site-specific trend of recurrence showed that locoregional recurrence increased within 5 years in patients with pN0−2 disease but plateaued 3 years after surgery in patients with pN3 disease. Time to recurrence was significantly longer for the pN0 patients compared with the pN+ patients (median: 25 vs. 16 months, P=0.001). Moreover, post-recurrence survival was significantly better for the pN0 patients than for the pN+ patients (median: 12 vs. 6 months, P=0.001), especially in patients with non-peritoneal recurrence, late recurrence, single recurrence, and receipt of potential curative treatment.

Conclusions: Among clinicopathologic factors, lymph node status is the most important factor associated with recurrence patterns after curative gastrectomy. Lymph node status may be used as an adjunct in clinical decision-making about postoperative therapeutic and follow-up strategies.

Keywords: Recurrence patterns; lymph node status; post-recurrence survival; recurrence-free survival; gastric cancer

Submitted Jan 25, 2021. Accepted for publication May 10, 2021.
doi: 10.21147/j.issn.1000-9604.2021.03.05

View this article at: https://doi.org/10.21147/j.issn.1000-9604.2021.03.05

Introduction

There were over 1,000,000 new cases of gastric cancer (GC) and an estimated 783,000 deaths caused by GC (equating to 1 in every 12 deaths globally) in 2018, making it the fifth most frequently diagnosed cancer and the third
leading surgical techniques and perioperative care have led to decreased operative mortality and morbidity (3,4), the long-term prognosis of GC remains poor (5,6). Moreover, adjuvant chemotherapy or radiotherapy is less effective against GC than other solid malignancies because of the heterogeneity of tumor biology (7). As a main cause of GC-related death, recurrence after curative gastrectomy was reported to occur in 20%–50% of patients (5,6,8-10).

Therefore, early detection of recurrence as well as positive treatment is critical in achieving a good prognosis (11,12).

In practice, treatment and follow-up strategies for patients with GC after curative-intent resection are generally conducted based on the pathologic stage (13). However, patterns of recurrence always vary among patients with GC who had the same pathologic stage and similar treatment regimens (5,6,9,10). Thus, clinicopathologic factors associated with recurrence patterns have been extensively investigated (9,10). To our knowledge, data on the timing and site(s) of recurrence are helpful in conducting effective follow-up examinations. For example, Seo et al. proposed a risk-scoring system based on the extragastric recurrence of early GC to stratify postsurgical computed tomography (CT) surveillance, which can reduce the possible risk associated with radiation exposure as well as additional cost and time (14).

Lymph node status is one of the most important prognostic factors in patients with various malignancies, including GC (15-17). Several studies have demonstrated that lymph node status greatly affects patterns of recurrence in several cancers (18,19). However, patterns of recurrence in node-negative versus node-positive patients with GC have not been well characterized. In this study, using a prospectively collected database from a high-volume center, we sought to examine the impact of lymph node status on the patterns of recurrence and to identify potential factors predicting overall survival (OS) after recurrence.

Materials and methods

Study population and data collection

We retrospectively reviewed patients undergoing curative resection for GC at the Fujian Medical University Union Hospital (FMUUH) between January 2010 and August 2014. Patients who met the following criteria were included: 1) no evidence of peritoneal dissemination or distant metastasis at diagnosis; 2) gastric adenocarcinoma confirmed by histopathology; 3) D2 lymph node dissection; and 4) R0 resection. Patients were excluded if they met the following criteria: 1) concurrent malignant disease of other organs (n=16); 2) preoperative chemotherapy (n=58); 3) previous gastrectomy (n=46); 4) T4b disease (n=22); 5) postoperative death within 30 d (n=14); or 6) incomplete medical records or follow-up data (n=20). Patients with incomplete data on recurrence (n=26) were also excluded. Finally, a total of 1,694 patients were enrolled in this study (Supplementary Figure S1). All surgical procedures, including D2 lymph node dissection, were performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer (13), while staging was performed according to the TNM classification [American Joint Committee on Cancer (AJCC), 8th edition] (20). Patients with advanced GC were routinely recommended to receive 6–8 cycles of 5-fluorouracil (5-FU)-based adjuvant chemotherapy [Oxaliplatin plus Capecitabine or S-1 (XELOX/SOX)] after surgery every 3 weeks. The regimen consisted of an intravenous infusion of Oxaliplatin 130 mg/m² on d 1 and the oral administration of Capecitabine 1,000 mg/m² twice daily on d 1–14 or the oral administration of S-1 40–60 mg twice daily on d 1–14 (21).

Drug toxicities were routinely recorded before the initiation of each cycle. Data on demographics and clinicopathologic results were obtained from a large-scale prospective database. Patients were divided into pN0, pN1, pN2, pN3a, and pN3b groups according to the number of positive lymph nodes. Additionally, patients with pT1–2 disease were only divided into pN0 and pN+ groups due to a small sample size. This study was reviewed and approved by the FMUUH Institutional Review Board. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.

Follow-up investigation

All patients were followed up postoperatively by physical examination, laboratory tests [including carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, and CA 72-4], and imaging examination [including chest radiography or chest CT, abdominal ultrasonography or abdominopelvic CT/magnetic resonance imaging (MRI), if necessary] every...
3 months for 2 years, every 6 months during the 3rd–5th year, and annually thereafter. In addition, annual endoscopy was recommended annually. Postoperative follow-up strategies in FMUUH are detailed in Supplementary Table S1. The follow-up period was completed in August 2019. The median follow-up time was 68 (range, 2–113) months. OS was defined as the time interval from surgery to death from any cause or to the last follow-up. Recurrence-free survival (RFS) was defined as the time interval from surgery to recurrence or to the last follow-up.

**Definition and categorization of recurrence**

Recurrences were categorized as locoregional, peritoneal, or distant recurrence (5,9). Locoregional recurrence included anastomotic or gastric remnant recurrence, and regional lymph nodes. Peritoneal recurrence was indicated by positive cytology in ascitic fluid or by a convincing presence of peritoneal nodules on cross-sectional imaging as determined by the radiology report. Distant metastasis was further defined according to the specific organ involved. Cervical lymph nodes or abdominal nodes beyond the upper retroperitoneum were considered distant metastases. Mediastinal lymph node recurrence was considered locoregional for gastroesophageal junction tumors and distant metastasis for all other tumors. Tumors involving the ovaries were considered peritoneal recurrence. The presence of recurrent disease in two or more sites was defined as multiple recurrences. Multiple recurrent lesions in the same area (e.g., liver) were not classified as having multiple recurrences. Although some patients had multiple recurrence episodes, this study analyzed the initial recurrence episode as defined above. According to our previous study, recurrence within 12 months after surgery was defined as early recurrence, and recurrence more than 12 months after surgery was defined as late recurrence (22).

**Treatment of recurrent disease**

At FMUUH, patients with recurrent disease were treated by a professional multidisciplinary team (MDT) including surgical oncologists, medical oncologists, radiologists, pathologists, and nutritionists. Curative-intent resections were performed only when recurrent tumors could be completely resected. Systemic chemotherapy was routinely recommended for patients with good performance status and adequate organ functions. For patients with bad performance status or inadequate organ functions, best supportive treatment like pain relief and nutritional support would be performed to improve the quality of life.

**Statistical analysis**

The primary endpoint of the present study was the patterns of initial recurrence. The secondary endpoints were RFS, OS, and post-recurrence survival (PRS). Continuous variables were compared using Student’s t test, and categorical variables were assessed using the $\chi^2$ test or Fisher’s exact test. Logistic regression was used for multivariate analysis of clinicopathologic factors associated with sites of initial recurrence. When exploring risk factors for sites of initial recurrence, the case group comprised all patients who experienced recurrence at the certain site (locoregional, peritoneum, or distant), including those who had multiple recurrences, while the control group comprised the remaining patients. Pearson’s correlation test was performed to identify variables associated with time to recurrence at univariate analysis, then multiple linear regression analysis was developed by using enter method (23). The Kaplan-Meier method was used to analyze OS and DFS, and the differences were assessed with log-rank tests. Univariate and multivariate analysis were performed using the Cox proportional hazards model to identify predictors of survival. Variables with a value of $P<0.1$ in the univariate analysis were included in the subsequent multivariate analysis. Two-tailed $P<0.05$ was considered statistically significant. All statistical analyses were conducted with SPSS software (Version 18.0; SPSS Inc., Chicago, IL, USA).

**Results**

**Clinicopathologic and treatment characteristics**

In the present study, we reviewed 1,694 patients with gastric adenocarcinoma who underwent curative-intent resection and met our inclusion criteria between January 2010 and August 2014 at FMUUH. Of these, 1,269 patients (74.9%) were males, and 425 (25.1%) were females. The mean age at the time of surgery was 60.7 years [standard derivation (SD) 11.3 years]. According to the pathologic results, 521 (30.8%) patients were classified as stage I, 404 (23.8%) as stage II, and 769 (45.4%) as stage III; 655 patients (38.7%) had node-negative disease, and 1,039 (61.3%) had node-positive disease (Supplementary Table S2). After a median follow-up of 68 [interquartile range (IQR) 33–113] months, 1,039 (61.3%) had node-positive disease (Supplementary Table S1). After a median follow-up of 68 [interquartile range (IQR) 33–113] months, 1,039 (61.3%) had node-positive disease (Supplementary Table S1).
range (IQR, 41–86) months, 517 patients (30.5%) developed recurrent disease. Complete data on recurrence could be obtained in 493 (95.4%) patients. The clinicopathological and treatment characteristics for these 493 patients are summarized in Table 1.

**OS and RFS**

For all patients (excluding 24 patients with incomplete data on recurrence), the 5-year OS was 70.9%, and the 5-year RFS was 71.9%. The 5-year OS rates in the pN0 and pN+ groups were 87.9% and 52.9%, respectively, and the 5-year RFS rates were 93.7% and 55.7%, respectively (log-rank P<0.001). In multivariate analysis, more advanced pN stage, more advanced pT stage, larger tumors, and no adjuvant chemotherapy were significantly associated with disease recurrence (all P<0.05; Supplementary Table S3).

**Pattern of recurrence according to pN stage**

Figure 1 illustrates the pattern of initial recurrence for all patients. Overall, 406 (82.4%) patients experienced recurrence involving a single area, 79 (16.0%) patients experienced recurrence involving two areas, and 8 (1.6%) patients experienced recurrence involving all three areas. Distant metastasis occurred in 312 (63.3%) patients, peritoneal recurrence in 147 (29.8%) patients, and locoregional recurrence in 129 (26.2%) patients. Figure 2 presents the sites of initial recurrence in detail. Distant metastasis was the most common site of initial recurrence in the pN+ group (including pN1, pN2, pN3a, and pN3b groups, all P<0.01), whereas the proportion in the three (locoregional, peritoneal, and distant) sites was similar in the pN0 group (Figure 2A). Compared with pN+ patients, pN0 patients had a significantly higher proportion of locoregional recurrence [40.9% vs. 24.7%, odds ratio (OR): 2.108, 95% confidence interval (95% CI), 1.114–3.990, P=0.020], a significantly lower proportion of distant metastasis (43.2% vs. 65.3%, OR: 0.405, 95% CI, 0.216–0.758, P=0.004), and a comparable proportion of peritoneal recurrence (29.5% vs. 29.8%, OR: 0.986, 95% CI, 0.500–1.943, P=0.967). We next performed a stratified analysis according to pT stage. The proportion of distant metastasis was higher than that of locoregional or peritoneal recurrence in pN+ patients irrespective of pT stage (significant difference was not found only in pT4aN1 patients). For the pN0 patients, locoregional recurrence was the most common site of initial recurrence in patients with pT1–2 disease (57.1%), followed by distant recurrence (42.9%) and peritoneal recurrence (14.3%); distant metastasis was the most common site in patients with pT3 disease (57.1%), followed by locoregional recurrence (38.1%) and peritoneal recurrence (23.9%); peritoneal recurrence was the most common site in patients with pT4a disease (66.7%), followed by locoregional recurrence (22.2%) and distant recurrence (11.1%) (Figure 2B–D). We next investigated the impact of adjuvant chemotherapy on sites of initial recurrence in Supplementary Figure S2. There was no significant difference in the sites of recurrence between the pN0 and pN+ patients.

Then we performed the univariate and multivariate analysis of clinicopathologic factors associated with sites of initial recurrence in Supplementary Table S4. The results showed that patients with pN0 disease and tumors located in lower 1/3 had a significantly increased risk of locoregional recurrence. Predictive factors for distant recurrence included older age, well/moderate differentiation, pN+ disease, and lack of neural invasion. Several factors were associated with an increased risk of peritoneal recurrence including younger age, female sex, poorly differentiation/signet ring cell, more advanced T stage, and neural invasion (all P<0.05).

**Trends of recurrence according to pN stage**

Time-varying distributions of recurrence patterns are depicted in Supplementary Figure S3. Distant metastasis was the most common site of initial recurrence in different periods. Figure 3 shows the trends of the initial recurrence pattern over time in each pN stage. The number of patients with distant metastasis continued to increase within 5 years after surgery, irrespective of pN stage. Most peritoneal recurrence occurred within 3 years after surgery. Notably, the number of locoregional recurrence continued to increase within 5 years after surgery in patients with pN0–2 disease but plateaued 3 years after surgery in patients with pN3 disease.

**Time to recurrence according to pN stage**

The median time to initial recurrence for all patients was 16 (IQR, 9–28) months. The time to recurrence was significantly longer for the pN0 group compared with the pN+ group (median: 25 vs. 16 months, P=0.001). Patients with advanced pN stage were likely to experience recurrence early (P<0.001 for linear trend, Figure 4). For patients with pT1–2 disease, the pN0 group had a longer recurrence time than the pN+ group (median: 26 vs. 18 months).
Table 1 Clinicopathological characteristics of patients with recurrence according to lymph node status (N=493)

| Variables                                | Total       | pN0          | pN+          | P       |
|-------------------------------------------|-------------|--------------|--------------|---------|
| **Age at recurrence (year)**              | 63.5±11.7   | 65.2±13.9    | 63.3±11.5    | 0.295   |
| **Gender**                                |             |              |              | 0.470   |
| Male                                      | 370 (75.1)  | 35 (79.5)    | 335 (74.6)   |         |
| Female                                    | 123 (24.9)  | 9 (20.5)     | 114 (25.4)   |         |
| **Differentiation**                       |             |              |              | 0.051   |
| Well/moderate                             | 180 (36.5)  | 22 (50.0)    | 158 (35.2)   |         |
| Poorly/signet ring cell                   | 313 (63.5)  | 22 (50.0)    | 291 (64.8)   |         |
| **T stage**                               |             |              |              | <0.001  |
| T1                                        | 17 (3.4)    | 11 (25.0)    | 6 (1.3)      |         |
| T2                                        | 23 (4.7)    | 3 (6.8)      | 20 (4.5)     |         |
| T3                                        | 175 (35.5)  | 21 (47.7)    | 154 (34.3)   |         |
| T4a                                       | 278 (56.4)  | 9 (20.5)     | 269 (59.9)   |         |
| **N stage**                               |             |              |              |         |
| N0                                        | 44 (8.9)    | 44 (100)     | –            |         |
| N1                                        | 45 (9.1)    | –            | 45 (10.0)    |         |
| N2                                        | 93 (18.9)   | –            | 93 (20.7)    |         |
| N3a                                       | 176 (35.7)  | –            | 176 (39.2)   |         |
| N3b                                       | 135 (27.4)  | –            | 135 (30.1)   |         |
| **Tumor size (mm)**                       | 58.3±24.0   | 43.5±30.9    | 59.8±22.7    | <0.001  |
| **Tumor location**                        |             |              |              | 0.497   |
| Lower                                     | 180 (36.5)  | 16 (36.4)    | 164 (36.5)   |         |
| Middle                                    | 110 (22.3)  | 7 (15.9)     | 103 (22.9)   |         |
| Upper                                     | 116 (23.5)  | 10 (22.7)    | 106 (23.6)   |         |
| Mixed                                     | 87 (17.6)   | 11 (25.0)    | 76 (16.9)    |         |
| **Lymphovascular invasion**               |             |              |              | 0.075   |
| No                                        | 285 (57.8)  | 31 (70.5)    | 254 (56.6)   |         |
| Yes                                       | 208 (42.2)  | 13 (29.5)    | 195 (43.4)   |         |
| **Neural invasion**                       |             |              |              | 0.281   |
| No                                        | 346 (70.2)  | 34 (77.3)    | 312 (69.5)   |         |
| Yes                                       | 147 (29.8)  | 10 (22.7)    | 137 (30.5)   |         |
| **Adjuvant chemotherapy**                 |             |              |              | <0.001  |
| No                                        | 132 (26.8)  | 22 (50.0)    | 110 (24.5)   |         |
| Yes                                       | 361 (73.2)  | 22 (50.0)    | 339 (75.5)   |         |
| **Time to recurrence (month)**            | 16 (9–28)   | 26 (14–41)   | 15 (9–27)    | 0.001   |
| **Symptom(s) of recurrence**              |             |              |              | 0.304   |
| Asymptomatic                              | 146 (29.6)  | 16 (36.4)    | 130 (29.0)   |         |
| Symptomatic                               | 347 (70.4)  | 28 (63.6)    | 319 (71.0)   |         |
| **Number of metastasis site(s)**          |             |              |              | 0.552   |
| 1 site                                    | 339 (68.8)  | 32 (72.7)    | 307 (68.4)   |         |
| ≥2 sites                                  | 154 (31.2)  | 12 (27.3)    | 142 (31.6)   |         |
| **Treatment of recurrence**               |             |              |              | 0.215   |
| Support treatment only                    | 150 (30.4)  | 17 (38.6)    | 133 (29.6)   |         |
| Potential curative treatment              | 343 (69.6)  | 27 (61.4)    | 316 (70.4)   |         |

IQR, interquartile range.
months), but the difference was not statistically significant (P=0.163). For patients with pT3−4a disease, more advanced pN disease was significantly associated with a shorter time to recurrence (P<0.001 for linear trend, P=0.006, respectively). Moreover, the time to recurrence was similar between patients who receive adjuvant chemotherapy and those who did not (all P>0.05, Supplementary Figure S4). In the multivariate linear regression model, only lymph node status was an independent factor for recurrence time (B: −7.054, 95% CI, −12.643, −1.465, P=0.013, Supplementary Table S5).

PRS after recurrence according to pN stage

The median PRS was 6 (IQR, 3−15) months. PRS was significantly better for pN0 patients compared to pN+ patients (median: 12 vs. 6 months, P<0.001). We next analyzed clinicopathologic and treatment factors associated with PRS. In univariate analysis, older age at recurrence, more advanced pT disease, more advanced pN disease, larger tumors, the presence of symptoms, early recurrence, multiple recurrences, and support treatment only were associated with poorer survival. After adjusting for these factors, advanced pN disease, the presence of symptoms, early recurrence, multiple recurrences, and support treatment only remained independent risk factors for PRS (all P<0.05, Table 2). A forest plot was further established to perform a subgroup analysis. The results revealed that pN0 disease exhibited a significant OS benefit among patients with non-peritoneal recurrence, late recurrence, single recurrence, and receipt of potential curative treatment (all P<0.05, Supplementary Figure S5).

Discussion

In the present study, we compared recurrence patterns and PRS between pN0 and pN+ groups after curative resection for GC. Patients in the pN+ group had a significantly lower

Figure 1 Venn diagram of recurrence patterns in 493 patients.

Figure 2 Patterns of initial recurrence according to pN stage in (A) all; (B) pT1−2; (C) pT3; (D) pT4a patients. **, P<0.01; *, P<0.05.
risk of locoregional recurrence but a significantly higher risk of distant metastasis. For the pN+ group, the proportion of distant metastasis was higher than that of locoregional or peritoneal recurrence irrespective of pT stage. In contrast, the patterns of recurrence depended on pT stage for the pN0 group. Distant metastasis increased within 5 years after surgery in both the pN0 and pN+ groups; peritoneal recurrence mostly occurred within 3 years; locoregional recurrence increased within 5 years in patients with pN0–2 disease but plateaued 3 years after surgery in patients with pN3 disease. The time to recurrence was significantly longer for the pN0 group compared with the pN+ group. Moreover, PRS in the pN0 group was significantly better for the pN+ group, especially in patients with non-peritoneal recurrence, late recurrence, single recurrence, and receipt of potential curative treatment. These results can assist in the clinical decision-making about individualized therapeutic and follow-up.

Figure 3 Cumulative numbers of patients with locoregional, peritoneal, and distant recurrence according to pN stage. (A) pN0; (B) pN1; (C) pN2; (D) pN3a; (E) pN3b.
Many previous studies have attempted to demonstrate the patterns of initial recurrence after curative resection for GC (5,6,9,10). However, the results were quite different because of the heterogeneity of the study population. Thus, the identification of specific clinicopathologic factors associated with recurrence patterns has become a hot topic. Lee et al. examined patients with gastric and gastroesophageal junction Siewert II or III adenocarcinoma who underwent potentially curative resection at the Memorial Sloan Kettering Cancer Center (MSKCC). In this study, Lauren histologic type proved the only significant factor that was associated with both peritoneal recurrence and distant metastasis (9). In a retrospective study of 656 patients with recurrent GC, Kim et al. found that the pattern of initial recurrence was also different according to the pathologic stage. Among patients with stage I GC, more than half had distant organ metastasis; distant metastasis was the most common pattern in patients with stage III GC (10). However, the effects of lymph node status and depth of tumor invasion on recurrence patterns after surgery appear to be inconsistent in clinical practice.

It was reported that T stage and N stage may have a significant interaction effect on patterns of recurrence (9). As a critical prognostic factor for disease recurrence and survival in resected GC, the impact of lymph node status itself on recurrence patterns remains unclear. Thus, the present study investigated the association between lymph node status and recurrence patterns. Compared with pN+ patients, pN0 patients had a significantly greater proportion of locoregional recurrence (40.9% vs. 24.7%; OR: 2.108; 95% CI, 1.114−3.990; P=0.020) and a significantly lower proportion of distant metastasis (43.2% vs. 65.3%; OR: 0.405; 95% CI, 0.216−0.758; P=0.004). According to the previous studies, tumor cells exit through lymph node blood vessels for systemic dissemination (24-26). Thus, for pN+ patients, the presence of lymph node metastasis is related to a higher risk of distant metastasis, which may lead to a relatively lower risk of locoregional recurrence. For pN+ patients, distant metastasis was the most common pattern irrespective of pT stage. In contrast, patterns of initial recurrence differed by pT stage for pN0 patients: locoregional recurrence was most common in patients with pT1−2 disease (57.1%), distant metastasis was
Table 2 Univariate and multivariate analyses for OS after recurrence

| Variables                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR (95% CI)         | P                     | HR (95% CI)         | P                     |
| Age at recurrence                | 1.009 (1.001−1.017) | 0.035                 | 1.003 (0.994−1.012) | 0.521                 |
| Gender                           |                     |                       |                      |                       |
| Male                             | Reference           |                       |                      |                       |
| Female                           | 1.024 (0.830−1.263) | 0.322                 |                       |                       |
| Differentiation                  |                     |                       |                      |                       |
| Well/moderate                    | Reference           |                       |                      |                       |
| Poorly/signet ring cell          | 1.100 (0.911−1.329) |                       |                       |                       |
| T stage                          |                     | <0.001                | 0.004                |                       |
| T1−2                             | Reference           |                       | Reference            |                       |
| T3                               | 1.510 (1.032−2.209) | 0.005                 | 1.358 (0.910−2.028)  | 0.300                 |
| T4a                              | 1.777 (1.229−2.571) |                       | 1.261 (0.830−1.915)  |                       |
| N stage                          |                     | <0.001                | 0.004                |                       |
| N0                               | Reference           |                       | Reference            |                       |
| N1                               | 1.371 (0.872−2.156) |                       | 1.535 (0.970−2.429)  |                       |
| N2                               | 1.749 (1.179−2.595) |                       | 1.933 (1.281−2.918)  |                       |
| N3a                              | 1.886 (1.307−2.721) |                       | 1.845 (1.245−2.736)  |                       |
| N3b                              | 2.329 (1.597−3.396) |                       | 2.235 (1.476−3.386)  |                       |
| Tumor size                       | 1.005 (1.001−1.008) | 0.008                 | 1.001 (0.997−1.006)  | 0.572                 |
| Tumor location                   | 0.605               |                       |                      |                       |
| Lower                            | Reference           |                       |                      |                       |
| Middle                           | 1.127 (0.882−1.441) |                       |                      |                       |
| Upper                            | 1.070 (0.842−1.361) |                       |                      |                       |
| Mixed                            | 1.183 (0.908−1.543) |                       |                      |                       |
| Lymphovascular invasion          |                     | 0.160                 |                       |                       |
| No                               | Reference           |                       |                      |                       |
| Yes                              | 1.141 (0.949−1.372) |                       |                      |                       |
| Neural invasion                  | 0.676               |                       |                      |                       |
| No                               | Reference           |                       |                      |                       |
| Yes                              | 1.043 (0.856−1.270) |                       |                      |                       |
| Adjuvant chemotherapy            |                     | 0.025                 | 0.881                |                       |
| No                               | Reference           |                       | Reference            |                       |
| Yes                              | 0.793 (0.648−0.971) | 0.983 (0.784−1.233)   | <0.001               |                       |
| Symptom(s) of recurrence         | <0.001              | <0.001                |                       |                       |
| Asymptomatic                     | Reference           |                       | Reference            |                       |
| Symptomatic                      | 2.044 (1.666−2.507) | 2.027 (1.637−2.510)   | <0.001               |                       |
| No. of metastasis site(s)        | 0.002               | <0.001                |                       |                       |
| 1 site                           | Reference           |                       | Reference            |                       |
| ≥2 sites                         | 1.375 (1.129−1.675) | 1.544 (1.257−1.896)   | <0.001               |                       |
| Time of recurrence               | 0.018               | 0.037                 |                       |                       |
| Within 1 years                   | Reference           |                       | Reference            |                       |
| ≥1 years                         | 0.795 (0.657−0.961) | 0.808 (0.661−0.987)   | <0.001               |                       |
| Treatment of recurrence          | <0.001              | <0.001                |                       |                       |
| Support treatment only           | Reference           |                       | Reference            |                       |
| Potential curative treatment     | 0.288 (0.234−0.355) | 0.265 (0.211−0.333)   |                       |                       |

OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval.
most common in patients with pT3 disease (57.1%), and peritoneal recurrence was most common in patients with pT4a disease (66.7%). A possible explanation is that a low peritoneal recurrence rate led to relatively high locoregional and distant recurrence rates in patients with pT1–2 disease, while a high peritoneal recurrence rate led to relatively low locoregional and distant recurrence rates in patients with serosal invasion (pT4a disease). Therefore, for node-negative patients, follow-up strategies should be considered according to pathologic T stage, while the key to follow-up for node-positive patients is distant metastasis. Furthermore, since adjuvant therapies focus on specific disease patterns (e.g. intraperitoneal chemotherapy for patients at high risk of peritoneal recurrence), understanding the pattern of recurrence is critical to the planning of adjuvant strategies.

It has been reported that the majority of GC recurrence develops within the first 2 years after surgery (27). Kang et al. investigated predictors of early recurrence (within 2 years) after surgery for GC and found that the proportion of early recurrence of pN+ patients was significantly higher than that of pN0 patients in both early and advanced GC (28). Sawayama et al. also demonstrated that early recurrence (within 12 months) was associated with a high lymph node ratio (metastasis/dissected lymph nodes) (29). In the present study, the time to recurrence was significantly longer for pN0 patients compared with pN+ patients (median: 25 vs. 16 months, P=0.001). In the multivariate analysis, only lymph node status was an independent predictor of time to recurrence. The prolonged duration between surgery and recurrence in node-negative tumors may be attributed to less aggressive disease biology. Thus, intensive follow-up in the early postoperative period may be unnecessary for node-negative patients. Furthermore, we found that distant metastasis increased within 5 years after surgery; peritoneal recurrence mostly occurred within 3 years; locoregional recurrence increased within 5 years after surgery in patients with pN0–2 disease but plateaued 3 years after surgery in patients with pN3 disease. This finding provides valuable information on follow-up strategies. First, more attention should be paid to distant metastasis in patients without disease recurrence 3 years after surgery. Second, more attention should also be paid to locoregional recurrence in patients with N0–2 disease.

Survival after recurrence of surgically resected GC remains poor in both Eastern and Western countries (9-12). Most patients succumbed within 1 year after receiving a diagnosis of recurrence. The median OS after a diagnosis of recurrence was 6 months in this study, which is similar to previous studies. Notably, PRS in pN0 patients was significantly better than that in pN+ patients (median: 12 vs. 6 months, P<0.001), especially in patients with non-peritoneal recurrence, late recurrence, single recurrence, and receipt of potential curative treatment (all P<0.05). Positive therapies are needed to treat recurrent disease in node-negative patients following curative surgical resection for GC.

Our study has several limitations. First, as a retrospective, single-institution study, it may have been subject to selection bias, and the validity and generalizability of our findings need to be established by testing it in other institutions. Second, although the probability is low, misdiagnosis of recurrence patterns may lead to deviations in results. Third, not all patients performed the follow-up strategies provided by the clinicians. Last, we did not perform the same analysis in patients receiving neoadjuvant chemotherapy (only 58 cases), which must be analyzed in the future.

Conclusions

Among clinicopathologic factors, lymph node status is the most important factor associated with recurrence patterns after curative gastrectomy. Lymph node status may be used as an adjunct in clinical decision-making about postoperative therapeutic and follow-up strategies.

Acknowledgements

This study was supported by Scientific and Technological Innovation Joint Capital Projects of Fujian Province, China (No. 2017Y9011), Minimally Invasive Medical Center of Fujian Province (No. [2017]171), Project supported by the Science Foundation of the Fujian Province, China (No. 2018J01307) and Joint Funds for the innovation of science and Technology, Fujian province (No. 2018Y9041).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Yang L, Ying X, Liu S, et al. Gastric cancer: Epidemiology, risk factors and prevention strategies. Chin J Cancer Res 2020;32:695-704.
3. Msika S, Tazi MA, Benhamiche AM, et al. Population-based study of diagnosis, treatment and prognosis of gastric cancer. Br J Surg 1997;84:1474-8.
4. Tegels JJ, De Maat MF, Hulsewé KW, et al. Improving the outcomes in gastric cancer surgery. World J Gastroenterol 2014;20:13692-704.
5. D’Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-16.
6. Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: A United States multi-institutional analysis. J Am Coll Surg 2014;219:664-75.
7. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
8. Lee SE, Ryu KW, Nam BH, et al. Prognostic significance of intraoperatively estimated surgical stage in curatively resected gastric cancer patients. J Am Coll Surg 2009;209:461-7.
9. Lee JH, Chang KK, Yoon C, et al. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg 2008;267:105-13.
10. Kim JH, Lee HH, Seo HS, et al. Stage-specific difference in timing and pattern of initial recurrence after curative surgery for gastric cancer. Surg Oncol 2019;30:81-6.
11. Bennett JJ, Gonen M, D’Angelica M, et al. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg 2005;201:503-10.
12. Villarreal-Garza C, Rojas-Flores M, Castro-Sánchez A, et al. Improved outcome in asymptomatic recurrence following curative surgery for gastric cancer. Med Oncol 2010;28:973-80.
13. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14:113-23.
14. Seo N, Han K, Hyung WJ, et al. Stratification of postsurgical computed tomography surveillance based on the extragastric recurrence of early gastric cancer. Ann Surg 2020;272:319-25.
15. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978;76:832-9.
16. Sutherland CM, Mather FJ. Long-term survival and prognostic factors in breast cancer patients with localized (no skin, muscle, or chest wall attachment) disease with and without positive lymph nodes. Cancer 1986;57:622-9.
17. Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-61.
18. Mahdi H, Jernigan A, Nutter B, et al. Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion. J Gynecol Oncol 2015;26:208-13.
19. Wang X, Luo Y, Li M, et al. Recurrence pattern of squamous cell carcinoma in the mid thoracic esophagus: implications for the clinical target volume design of postoperative radiotherapy. Onco Targets Ther 2016;9:6021-7.
20. Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer, 2017.
21. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-96.
22. Xu BB, Lu J, Zheng ZF, et al. The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data. Gastric Cancer 2019;22:1016-28.
23. Giretti I, Correani A, Antognoli L, et al. Blood urea in preterm infants on routine parenteral nutrition: A multiple linear regression analysis. Clin Nutr 2021;40:153-6.
24. Zhang XY, Lu WY. Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med 2014;11:247-54.
25. Brown M, Assen FP, Leithner A, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 2018;359:1408-11.

26. Pereira ER, Kedrin D, Seano G, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 2018;359:1403-7.

27. Feng XY, Chen YB, Wang W, et al. Time-varying pattern of recurrence risk for gastric cancer patients. Med Oncol 2013;30:514.

28. Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol 2015;21:5934-40.

29. Sawayama H, Iwatsuki M, Kuroda D, et al. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. Surg Today 2018;48:994-1003.

Cite this article as: Tang Y, Lin J, Lin J, Wang J, Lu J, Chen Q, Cao L, Lin M, Tu R, Huang C, Li P, Zheng C, Xie J. Reappraise role of lymph node status in patterns of recurrence following curative resection of gastric adenocarcinoma. Chin J Cancer Res 2021;33(3):331-342. doi: 10.21147/j.issn.1000-9604.2021.03.05
Figure S1 Diagram of study population.

Figure S2 Patterns of initial recurrence according to receipt of AC in (A) all; (B) pN0; and (C) pN+ patients. AC, adjuvant chemotherapy.

Figure S3 Time-varying distributions of recurrence pattern.
Figure S4 Timing of initial recurrence after surgery according to receipt of AC in (A) all; (B) pN0; and (C) pN+ patients. AC, adjuvant chemotherapy.

Figure S5 Forest plot showing the impact of lymph node status on post-recurrence survival stratified by different clinicopathological factors. Hazard ratios with 95% CI are shown for pN+ cohort vs. pN0 cohort. 95% CI, 95% confidence interval.
| Examinations                           | 1  | 3  | 6  | 9  | 12 | 15 | 18 | 21 | 24 | 30 | 36 | 42 | 48 | 54 | 60 |
|---------------------------------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Medical examination, PS, body weight  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  |
| Blood test including tumor markers    | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  |
| Chest and abdominopelvic CT          | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  |
| Chest radiography and abdominal US    | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  |
| Endoscopy                             | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  | Ω  |

Examinations to be considered when needs arise: MRI, bone scintigram, PET scan, etc. PS, performance status; CT, computed tomography; US, ultrasonography; MRI, magnetic resonance imaging; PET, positron emission tomography; Ω, the time points at which the specific examinations are performed after surgery.
| Variables                                      | Total      | pN0       | pN+       | P       |
|------------------------------------------------|------------|-----------|-----------|---------|
| Age at diagnosis (year) (±SD)                  | 60.7±11.3  | 60.2±11.2 | 61.0±11.3 | 0.133   |
| Gender                                         |            |           |           | 0.338   |
| Male                                           | 1,269 (74.9)| 499 (76.2)| 770 (74.1)|         |
| Female                                         | 425 (25.1) | 156 (23.8)| 269 (25.9)|         |
| Differentiation                                |            |           | <0.001    |         |
| Well/moderate                                  | 821 (48.5) | 412 (62.9)| 409 (39.4)|         |
| Poorly/signet ring cell                        | 873 (51.5) | 243 (37.1)| 630 (60.6)|         |
| Surgical procedure                             |            |           | <0.001    |         |
| Total gastrectomy                              | 831 (49.1) | 253 (38.6)| 578 (55.6)|         |
| Distal gastrectomy                             | 823 (48.6) | 373 (56.9)| 450 (43.3)|         |
| Proximal gastrectomy                           | 40 (2.4)   | 29 (4.4)  | 11 (1.1)  |         |
| T stage                                        |            |           | <0.001    |         |
| T1                                             | 450 (26.6) | 376 (57.4)| 74 (7.1)  |         |
| T2                                             | 195 (11.5) | 95 (14.5) | 100 (9.6) |         |
| T3                                             | 548 (32.3) | 125 (19.1)| 423 (40.7)|         |
| T4a                                            | 501 (29.6) | 59 (9.0)  | 442 (42.5)|         |
| N stage                                        |            |           |           | <0.001  |
| N0                                             | 655 (38.7) | 655 (100)| –         |         |
| N1                                             | 269 (15.9) | –         | 269 (25.9)|         |
| N2                                             | 272 (16.1) | –         | 272 (26.2)|         |
| N3a                                            | 307 (18.1) | –         | 307 (29.5)|         |
| N3b                                            | 191 (11.3) | –         | 191 (18.4)|         |
| Tumor stage                                    |            |           |           | <0.001  |
| I                                              | 521 (30.8) | 471 (71.9)| 50 (4.8)  |         |
| II                                             | 404 (23.8) | 184 (28.1)| 220 (21.2)|         |
| III                                            | 769 (45.4) | –         | 769 (74.0)|         |
| Lymph node retrieved (n) (±SD)                 | 35.3±13.7  | 32.4±12.3 | 37.1±14.2 | <0.001  |
| Tumor size (mm) (±SD)                          | 43.1±24.5  | 28.4±17.7 | 52.4±23.6 | <0.001  |
| Tumor location                                 |            |           | <0.001    |         |
| Lower                                          | 742 (43.8) | 327 (49.9)| 415 (39.9)|         |
| Middle                                         | 352 (20.8) | 115 (17.6)| 237 (22.8)|         |
| Upper                                          | 391 (23.1) | 145 (22.1)| 246 (23.7)|         |
| Mixed                                          | 209 (12.3) | 68 (10.4) | 141 (13.6)|         |
| Lymphovascular invasion                       |            |           | <0.001    |         |
| No                                             | 1,229 (72.6)| 588 (89.8)| 641 (61.7)|         |
| Yes                                            | 465 (27.4) | 67 (10.2) | 398 (38.3)|         |
| Neural invasion                                |            |           | <0.001    |         |
| No                                             | 1,374 (81.1)| 613 (93.6)| 761 (73.2)|         |
| Yes                                            | 320 (18.9) | 42 (6.4)  | 278 (26.8)|         |
| Postoperative complications                    |            |           | 0.924     |         |
| No                                             | 1,352 (79.8)| 522 (79.7)| 830 (79.9)|         |
| Yes                                            | 342 (20.2) | 133 (20.3)| 209 (20.1)|         |
| Adjuvant chemotherapy                          |            |           | <0.001    |         |
| No                                             | 695 (41.0) | 482 (73.6)| 213 (20.5)|         |
| Yes                                            | 999 (59.0) | 173 (26.4)| 826 (79.5)|         |
Table S3 Univariate and multivariate analyses of factors associated with recurrence

| Variables                        | Univariate analysis |         |         | Multivariate analysis |         |
|----------------------------------|---------------------|---------|---------|-----------------------|---------|
|                                  | HR (95% CI)         | P       | HR (95% CI) | P       |
| Age at diagnosis                 | 1.012 (1.004–1.021) | 0.003   | 1.007 (0.999–1.015) | 0.104   |
| Gender                           |                     |         |         |                       |         |
| Male                             | Reference           |         |         |                       |         |
| Female                           | 0.998 (0.813–1.225) |         |         |                       |         |
| Differentiation                  |                     | <0.001  |         | 0.430                 |         |
| Well/moderate                    | Reference           |         |         | Reference             |         |
| Poorly/signet ring cell          | 1.849 (1.539–2.221) |         | 0.923 (0.758–1.125) |         |
| T stage                          |                     | <0.001  |         | <0.001                |         |
| T1                               | Reference           |         |         | Reference             |         |
| T2                               | 3.396 (1.825–6.322) |         | 2.423 (1.273–4.615) |         |
| T3                               | 10.350 (6.288–17.035)|         | 4.135 (2.354–7.264) |         |
| T4a                              | 22.650 (13.874–36.978)|         | 6.670 (3.758–11.837) |         |
| N stage                          |                     | <0.001  |         | <0.001                |         |
| N0                               | Reference           |         |         | Reference             |         |
| N1                               | 2.698 (1.780–4.088) |         | 1.866 (1.200–2.902) |         |
| N2                               | 6.063 (4.235–8.679) |         | 3.123 (2.092–4.663) |         |
| N3a                              | 13.314 (9.560–18.542)|         | 6.096 (4.127–9.003) |         |
| N3b                              | 21.329 (15.144–30.039)|       | 8.528 (5.586–13.018) |         |
| Tumor size                       | 1.025 (1.022–1.027) | <0.001  | 1.006 (1.002–1.011) | 0.002   |
| Tumor location                   |                     | <0.001  |         | 0.760                 |         |
| Lower                            | Reference           |         |         | Reference             |         |
| Middle                           | 1.393 (1.099–1.767) |         | 0.880 (0.690–1.122) |         |
| Upper                            | 1.318 (1.043–1.664) |         | 0.918 (0.722–1.168) |         |
| Mixed                            | 2.007 (1.554–2.593) |         | 0.936 (0.708–1.237) |         |
| Lymphovascular invasion          |                     | <0.001  |         | 0.640                 |         |
| No                               | Reference           |         |         | Reference             |         |
| Yes                              | 2.336 (1.953–2.793) |         | 1.049 (0.859–1.280) |         |
| Neural invasion                  |                     | <0.001  |         | 0.450                 |         |
| No                               | Reference           |         |         | Reference             |         |
| Yes                              | 2.217 (1.826–2.692) |         | 1.084 (0.879–1.337) |         |
| Adjuvant chemotherapy            |                     | <0.001  |         | <0.001                |         |
| No                               | Reference           |         |         | Reference             |         |
| Yes                              | 2.104 (1.723–2.570) |         | 0.642 (0.514–0.801) |         |

HR, Hazard ratio; 95% CI, 95% confidence interval.
Table S4  Univariate and multivariate analysis of clinicopathologic factors associated with sites of initial recurrence

| Variables                      | Locoregional Univariate analysis | Locoregional Multivariate analysis | Peritoneal Univariate analysis | Peritoneal Multivariate analysis | Distant Univariate analysis | Distant Multivariate analysis |
|--------------------------------|----------------------------------|-----------------------------------|-------------------------------|----------------------------------|----------------------------|-------------------------------|
| Age at diagnosis               | 0.999 (0.982–1.017)             | 0.960 (0.944–0.977)              | 0.970 (0.953–0.989)          | 1.025 (1.009–1.042)             | 1.022 (1.004–1.040)         |
| Gender                         |                                  |                                   |                               |                                  |                            |                               |
| Male                           | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| Female                         | 0.883 (0.551–1.415)             | 2.444 (1.595–3.744)              | 1.673 (1.045–2.679)          | 0.668 (0.441–1.012)             | 0.876 (0.555–1.383)         |
| Differentiation                |                                  |                                   |                               |                                  |                            |                               |
| Well/moderate                  | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| Poorly/signet ring cell        | 1.265 (0.827–1.934)             | 2.308 (1.493–3.568)              | 1.672 (1.046–2.674)          | 0.557 (0.375–0.826)             | 0.585 (0.383–0.894)         |
| T stage                        |                                  |                                   |                               |                                  |                            |                               |
| T1–2                           | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| T3–4                           | 0.847 (0.345–2.080)             | 5.748 (1.743–18.951)             | 3.536 (1.025–12.206)         | 0.720 (0.357–1.454)             |                            |                               |
| N stage                        |                                   |                                   |                               |                                  |                            |                               |
| N0                             | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| N+                             | 0.474 (0.251–0.898)             | 0.456 (0.232–0.896)              | 1.014 (0.515–1.999)          | 2.471 (1.320–4.628)             | 3.222 (1.656–6.269)         |
| Tumor size                     | 0.991 (0.983–1.000)             | 0.999                            | 1.010 (1.002–1.018)          | 1.007 (0.997–1.016)             | 0.999                      |
| Tumor location                 |                                   |                                   |                               |                                  |                            |                               |
| Lower                          | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| Middle                         | 0.589 (0.344–1.008)             | 0.608 (0.351–1.054)              | 1.498 (0.910–2.465)          | 1.227 (0.713–2.111)             | 1.096 (0.676–1.776)         | 1.120 (0.676–1.856)         |
| Upper                          | 0.577 (0.340–0.980)             | 0.581 (0.339–0.996)              | 0.546 (0.311–0.959)          | 0.617 (0.338–1.126)             | 1.918 (0.978–2.802)         | 1.656                             |
| Mixed                          | 0.365 (0.191–0.699)             | 0.359 (0.178–0.723)              | 1.107 (0.638–1.922)          | 0.789 (0.420–1.483)             | 1.462 (0.856–2.495)         | 1.733 (0.986–3.049)         |
| Lymphovascular invasion        |                                   |                                   |                               |                                  |                            |                               |
| No                             | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| Yes                            | 1.216 (0.812–1.823)             | 0.999                            | 1.089                        |                                |                            |                               |
| Neural invasion                |                                   |                                   |                               |                                  |                            |                               |
| No                             | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| Yes                            | 0.977 (0.629–1.517)             | 1.801 (1.196–2.713)              | 1.784 (1.149–2.770)          | 0.587 (0.395–0.870)             | 0.549 (0.364–0.829)         |
| Adjuvant chemotherapy          |                                   |                                   |                               |                                  |                            |                               |
| No                             | Reference                        | Reference                         | Reference                     | Reference                        | Reference                   | Reference                     |
| Yes                            | 0.925 (0.590–1.451)             | 1.313                            | 0.937                        |                                |                            |                               |

Significant results are indicated in bold.
Table S5 Multivariate linear regression model predicting time to recurrence

| Variables                                      | Univariate analysis | Multivariate analysis |
|------------------------------------------------|---------------------|-----------------------|
|                                                | Pearson’s correlation | P   | B (95% CI)         | P   |
| Age at diagnosis                               | −0.024              | 0.445                 | −3.054 (−9.062, 2.954) | 0.318 |
| Gender (female vs. male)                       | −0.024              | 0.589                 | −7.054 (−12.643, −1.465) | 0.013 |
| Differentiation (poorly vs. well/moderate)     | −0.017              | 0.714                 | -              |      |
| T stage (T3–4 vs. T1–2)                        | −0.106              | 0.018                 | -              |      |
| N stage (N+ vs. N0)                            | −0.146              | 0.001                 | −7.054 (−12.643, −1.465) | 0.013 |
| Tumor size                                     | −0.125              | 0.005                 | −0.064 (−0.131, 0.003) | 0.060 |
| Tumor location (proximal vs. distal)           | 0.005               | 0.918                 | -              |      |
| Lymphovascular invasion (yes vs. no)           | −0.045              | 0.314                 | -              |      |
| Neural invasion (yes vs. no)                   | −0.042              | 0.347                 | -              |      |
| Adjuvant chemotherapy (yes vs. no)             | 0.002               | 0.969                 | -              |      |

95% CI, 95% confidence interval.